Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Participants in the 72-week STEP UP trial who received the increased Wegovy dose of 7.2 mg experienced a mean weight reduction of 21%, while a third of them reached 25% body weight loss. Adults with ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Chief Executive Antonio Filosa shuffled responsibilities within the Jeep parent company and he retained the role of head of North America and American brands. The electric-car maker launches a ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Find insight on Novo Nordisk, Bumrungrad Hospital, Riverstone Holdings, and more in the latest Market Talks covering Health ...